Dizal (Jiangsu) Pharmaceutical Co. Ltd.SSE: 688192

Report for Q1 2026

Apr 30, 2026 · Issued by Dizal (Jiangsu) Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 30, 2026

On 6ix: 6ix.com/news/report-for-q1-2026-553

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix

Earlier from Dizal (Jiangsu) Pharmaceutical

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood ConferenceApr 29
Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026Apr 21
Announcement on Resolutions of the 2025 Annual General MeetingApr 21
Announcement on the 2nd Vesting Results in the 3rd Vesting Period for Category I Incentive Objects of Those Initially Granted in the 2022 Restricted Stock Incentive Plan and Stock ListingApr 10
2025 Annual ReportMar 31

Later from Dizal (Jiangsu) Pharmaceutical

Announcement on Participation in the "Dialogue on Growth" 2025 and Q1 2026 Collective Performance BriefingMay 7
Announcement on Change of Sponsor Representative for Continuous SupervisionMay 12
Announcement on Voluntary Disclosure of Study Results of the Hematological Tumor Products, Golidocitinib Birelentinib, Being Selected To Present at the 2026 Annual Meeting of the European Hematology Association (EHA)May 14
Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Sunvozertinib as First-Line Monotherapy for EGFR Exon20ins Non-Small Cell Lung Cancer by the National Medical Products Administration and Its Inclusion in Priority ReviewMay 28
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung CancerMay 29

All Dizal (Jiangsu) Pharmaceutical news releases

Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.

Follow Dizal (Jiangsu) Pharmaceutical